National Development and Reform Commission issued the "Thirteenth Five-Year Plan" for the development of bio-industry
Release time: 2016-08-24
In January 2017, the Development and Reform Commission issued the "13th Five-Year Plan" for the development of the biological industry, which pointed out the direction of the key issues and development of the current biological industry. With clinical value as the core, we will carry out accurate supervision in the whole process of therapeutic indications and new target verification, preclinical and clinical trials, product design optimization and industrialization, provide safe and effective data information, and realize accurate drug research and development. Based on personal genomic information, combined with proteomic, metabolomic and other related internal environmental information, we integrate biological information bases at different data levels and use gene sequencing, imaging and big data analysis to achieve accurate prevention, diagnosis and treatment in prenatal fetal rare disease screening, tumors and genetic diseases. The plan also proposes the construction of a gene technology service center, which will provide a wide range of services for the treatment of rare prenatal fetal diseases, tumors and genetic diseases.
The plan also proposes to build a gene technology service center. In order to promote the application of gene technology, build a new health care support system, enhance the ability to prevent and treat diseases in China, according to geographical characteristics, reflect the policy guidance, relying on qualified medical institutions, R & D institutions with strong innovation capacity and advanced production enterprises, through the network layout, the construction of at least one gene technology application demonstration center in each province (district, city) to form a wide coverage, strong service capacity We will form a demonstration network of gene technology application with wide coverage and strong service capability, and promote the popularization of gene technology comprehensively and rapidly. The Gene Technology Application Demonstration Center focuses on high-throughput gene sequencing, mass spectrometry, medical imaging, gene editing, biosynthesis and other technologies, with emphasis on genetic screening and treatment of birth defects, early tumor screening and medication guidance, detection of infectious diseases and pathogenic microorganisms, and application of neonatal genetic ID cards, so that China can initially achieve comprehensive coverage of gene technology services and lay a solid foundation for individualized medicine.
Recommended news
Keep abreast of company news and industry news
In January 2017, the Development and Reform Commission issued the "13th Five-Year Plan" for the development of the biological industry, which pointed out the direction of the key issues and
6xHis Labeled Protein Nickel Column Purification Method Protocol
1. Solution preparation: 1.1 Binding Buffer: 10mM PB, 500mM NaCl, 10mM imidazole, pH7.4. 1.2 Elution Buffer1: 10mM PB, 500mM NaCl, 50mM imidazole, pH 7.4.
Jingcheng CrystaroseC FF filler test report
1、Apparatus and consumables 1.1 Instrument: JC-1 automated protein purification system (Jingcheng) 1.2 Chromatographic column: XK16 (GE) 1.3 Jingcheng Biotechnology: CrystaroseC FF(5ml)
Metal chelate chromatography affinity packing comparable to imported products
CrystaroseC FF metal chelate chromatography affinity packing has super high rigidity, higher linear flow rate up to 700cm/h, and the back pressure is close to the imported similar products or even lower. Therefore, the packing life is longer.
Contact us
E-mail：122460871@qq.com
Address: Building B, R&D Area, Wuhan National Biological Industry Base Project, No. 666 Gaoxin Avenue, East Lake High-tech Development Zone, Wuhan City
Copyright © Wuhan Jingcheng Biotechnology Co., LTD. Business License SEO This site supports IPV6